Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 1/20 | 0.71 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAT2A | P31153 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5746061 | 0.92 | TSPO (0.60) | TSPOMAT2A | |
| Hydrochloric Acid SCHEMBL4839588 | 0.91 | TSPO (0.59) | TSPOMAT2A | |
| SCHEMBL5702540 | 0.86 | TSPO (0.81) | TSPOMAPTMAT2A | |
| SCHEMBL7493004 | 0.86 | TSPO (0.61) | TSPOSMN1; SMN2ALDH1A1 | |
| SCHEMBL5747445 | 0.85 | TSPO (0.61) | TSPOSMN1; SMN2ALDH1A1 | |
| SCHEMBL4836958 | 0.85 | TSPO (0.61) | TSPOALDH1A1MAT2A | |
| Hydrochloric Acid SCHEMBL4841321 | 0.85 | TSPO (0.60) | TSPOSMN1; SMN2ALDH1A1 | |
| SCHEMBL197375 | 0.83 | TSPO (1.00) | TSPOMAPTMAT2A | |
| SCHEMBL7721134 | 0.83 | TSPO (0.76) | TSPOPOLBMAPT | |
| SCHEMBL5702522 | 0.82 | TSPO (0.74) | TSPOMAPTMAT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539169-A2 | AMYOTROPHIC LATERAL SCLEROSIS TREATMENT WITH CYCLOOXYGENASE-2 INHIBITORS | Pharmacia Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040063751-A1 | Combination therapy for the treatment of amyotrophic lateral sclerosis (ALS) with cyclooxygenase-2 (COX-2) inhibitor(s) and a second drug | PHARMACIA CORPORATION | 2004-04-01 | — | — | US | disclosed |
| WO-2003101380-A2 | AMYOTROPHIC LATERAL SCLEROSIS TREATMENT WITH CYCLOOXYGENASE-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063751-A1 | Combination therapy for the treatment of amyotrophic lateral sclerosis (ALS) with cyclooxygenase-2 (COX-2) inhibitor(s) and a second drug | SMN1; SMN2, PTGS2, PTGES2 | TSPO 2017/4885MAPK8 3673/4885LMNA 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.